CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
关于在 B 细胞急性淋巴细胞白血病中定义 CD19-CAR-T 细胞治疗后 B 细胞恢复的国际共识声明
英文原题：Harmonization on defining B-cell recovery post CD19-CAR T-cell therapy in B-cell acute lymphoblastic leukemia: An international consensus statement.
查看英文原题
Harmonization on defining B-cell recovery post CD19-CAR T-cell therapy in B-cell acute lymphoblastic leukemia: An international consensus statement.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CD19靶向CAR-T 细胞治疗（CD19-CAR）后复发仍然是复发/难治性B细胞急性淋巴细胞白血病长期治愈的主要障碍，近50%的患者在6个月内复发。通过CD19阳性细胞重新出现所检测到的早期B细胞恢复（BCR），与复发风险密切相关，并可作为CAR-T 细胞持续性丧失的替代标志物。然而，BCR的临床应用受到监测实践差异性的阻碍，包括各机构在定义、时机和测量方面的不一致。为弥补这一空白，我们召集了一个由儿科细胞治疗专家组成的国际工作组，以建立BCR的共识定义。我们的合作努力概述了BCR评估的标准化标准，旨在提高研究之间的可比性并指导CAR-T 细胞治疗后的监测策略。
展开英文摘要原文
Relapse following CD19-targeting chimeric antigen receptor T-cell therapy (CD19-CAR) remains a major barrier to long-term cure in relapsed/refractory B-cell acute lymphoblastic leukemia, with nearly 50% of patients relapsing within 6 months. Early B-cell recovery (BCR), as detected by the re-emergence of CD19-positive cells, has been strongly associated with relapse risk and serves as a surrogate marker for loss of CAR T-cell persistence.
However, clinical use of BCR is hindered by variability in monitoring practices, including inconsistent definitions, timing, and measurement across institutions. To address this gap, we convened an international working group of pediatric cellular therapy experts to establish a consensus definition for BCR.
Our collaborative effort outlines standardized criteria for BCR assessment aimed at improving comparability across studies and guiding post-CAR T-cell surveillance strategies.
论文信息
- 作者
- Lamble A、Bohling SD、Davis KL、Talleur AC、McNerney KO、Naik S、Kumar P、Thomas R
- 第一作者单位
- Division of Hematology and Oncology, Seattle Children's Hospital University of Washington Seattle Washington United States.United States
- 通讯作者单位
- Pediatric Oncology Branch, Center for Cancer Research National Cancer Institute Bethesda Maryland United States.United States
- 期刊
- HemaSphere2025 Nov
- 原文标识
- PubMed 41367923 · DOI 10.1002/hem3.70247
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →